Animal models of medullary thyroid cancer: State of the art and view to the future

Giovanni Vitale, Germano Gaudenzi, Luisa Circelli, Marco F. Manzoni, Andrea Bassi, Niccolò Fioritti, Antongiulio Faggiano, Annamaria Colao

Research output: Contribution to journalReview article

Abstract

Medullary thyroid carcinoma is a neuroendocrine tumour originating from parafollicular C cells accounting for 5-10% of thyroid cancers. Increased understanding of diseasespecific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid carcinoma. These drugs increase progression-free survival; however, they are often poorly tolerated and most treatment responses are transient. Animal models are indispensable tools for investigating the pathogenesis, mechanisms for tumour invasion and metastasis and new therapeutic approaches for cancer. Unfortunately, only few models are available for medullary thyroid carcinoma. This review provides an overview of the state of the art of animal models in medullary thyroid carcinoma and highlights future developments in this field, with the aim of addressing salient features and clinical relevance.

Original languageEnglish
Pages (from-to)R1-R12
JournalEndocrine-Related Cancer
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Animal Models
Drug Approval
Neuroendocrine Tumors
Thyroid Neoplasms
Disease-Free Survival
Neoplasms
Neoplasm Metastasis
Medullary Thyroid cancer
Therapeutics
Pharmaceutical Preparations

Keywords

  • Animal models
  • Chick chorioallantoic membrane
  • Drosophila melanogaster
  • Medullary thyroid cancer
  • Mice
  • Zebrafish

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Vitale, G., Gaudenzi, G., Circelli, L., Manzoni, M. F., Bassi, A., Fioritti, N., ... Colao, A. (2017). Animal models of medullary thyroid cancer: State of the art and view to the future. Endocrine-Related Cancer, 24(1), R1-R12. https://doi.org/10.1530/ERC-16-0399

Animal models of medullary thyroid cancer : State of the art and view to the future. / Vitale, Giovanni; Gaudenzi, Germano; Circelli, Luisa; Manzoni, Marco F.; Bassi, Andrea; Fioritti, Niccolò; Faggiano, Antongiulio; Colao, Annamaria.

In: Endocrine-Related Cancer, Vol. 24, No. 1, 01.01.2017, p. R1-R12.

Research output: Contribution to journalReview article

Vitale, G, Gaudenzi, G, Circelli, L, Manzoni, MF, Bassi, A, Fioritti, N, Faggiano, A & Colao, A 2017, 'Animal models of medullary thyroid cancer: State of the art and view to the future', Endocrine-Related Cancer, vol. 24, no. 1, pp. R1-R12. https://doi.org/10.1530/ERC-16-0399
Vitale G, Gaudenzi G, Circelli L, Manzoni MF, Bassi A, Fioritti N et al. Animal models of medullary thyroid cancer: State of the art and view to the future. Endocrine-Related Cancer. 2017 Jan 1;24(1):R1-R12. https://doi.org/10.1530/ERC-16-0399
Vitale, Giovanni ; Gaudenzi, Germano ; Circelli, Luisa ; Manzoni, Marco F. ; Bassi, Andrea ; Fioritti, Niccolò ; Faggiano, Antongiulio ; Colao, Annamaria. / Animal models of medullary thyroid cancer : State of the art and view to the future. In: Endocrine-Related Cancer. 2017 ; Vol. 24, No. 1. pp. R1-R12.
@article{cefa933ee4bd4f62b4d91f0a28c5f8e8,
title = "Animal models of medullary thyroid cancer: State of the art and view to the future",
abstract = "Medullary thyroid carcinoma is a neuroendocrine tumour originating from parafollicular C cells accounting for 5-10{\%} of thyroid cancers. Increased understanding of diseasespecific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid carcinoma. These drugs increase progression-free survival; however, they are often poorly tolerated and most treatment responses are transient. Animal models are indispensable tools for investigating the pathogenesis, mechanisms for tumour invasion and metastasis and new therapeutic approaches for cancer. Unfortunately, only few models are available for medullary thyroid carcinoma. This review provides an overview of the state of the art of animal models in medullary thyroid carcinoma and highlights future developments in this field, with the aim of addressing salient features and clinical relevance.",
keywords = "Animal models, Chick chorioallantoic membrane, Drosophila melanogaster, Medullary thyroid cancer, Mice, Zebrafish",
author = "Giovanni Vitale and Germano Gaudenzi and Luisa Circelli and Manzoni, {Marco F.} and Andrea Bassi and Niccol{\`o} Fioritti and Antongiulio Faggiano and Annamaria Colao",
year = "2017",
month = "1",
day = "1",
doi = "10.1530/ERC-16-0399",
language = "English",
volume = "24",
pages = "R1--R12",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Animal models of medullary thyroid cancer

T2 - State of the art and view to the future

AU - Vitale, Giovanni

AU - Gaudenzi, Germano

AU - Circelli, Luisa

AU - Manzoni, Marco F.

AU - Bassi, Andrea

AU - Fioritti, Niccolò

AU - Faggiano, Antongiulio

AU - Colao, Annamaria

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Medullary thyroid carcinoma is a neuroendocrine tumour originating from parafollicular C cells accounting for 5-10% of thyroid cancers. Increased understanding of diseasespecific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid carcinoma. These drugs increase progression-free survival; however, they are often poorly tolerated and most treatment responses are transient. Animal models are indispensable tools for investigating the pathogenesis, mechanisms for tumour invasion and metastasis and new therapeutic approaches for cancer. Unfortunately, only few models are available for medullary thyroid carcinoma. This review provides an overview of the state of the art of animal models in medullary thyroid carcinoma and highlights future developments in this field, with the aim of addressing salient features and clinical relevance.

AB - Medullary thyroid carcinoma is a neuroendocrine tumour originating from parafollicular C cells accounting for 5-10% of thyroid cancers. Increased understanding of diseasespecific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid carcinoma. These drugs increase progression-free survival; however, they are often poorly tolerated and most treatment responses are transient. Animal models are indispensable tools for investigating the pathogenesis, mechanisms for tumour invasion and metastasis and new therapeutic approaches for cancer. Unfortunately, only few models are available for medullary thyroid carcinoma. This review provides an overview of the state of the art of animal models in medullary thyroid carcinoma and highlights future developments in this field, with the aim of addressing salient features and clinical relevance.

KW - Animal models

KW - Chick chorioallantoic membrane

KW - Drosophila melanogaster

KW - Medullary thyroid cancer

KW - Mice

KW - Zebrafish

UR - http://www.scopus.com/inward/record.url?scp=85010698095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010698095&partnerID=8YFLogxK

U2 - 10.1530/ERC-16-0399

DO - 10.1530/ERC-16-0399

M3 - Review article

AN - SCOPUS:85010698095

VL - 24

SP - R1-R12

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 1

ER -